Automate Your Wheel Strategy on JAZZ
With Tiblio's Option Bot, you can configure your own wheel strategy including JAZZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JAZZ
- Rev/Share 66.7826
- Book/Share 60.5674
- PB 1.9338
- Debt/Equity 1.4659
- CurrentRatio 1.6176
- ROIC 0.0489
- MktCap 7104661950.0
- FreeCF/Share 20.6727
- PFCF 5.6161
- PE -17.7041
- Debt/Assets 0.4964
- DivYield 0
- ROE -0.1003
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JAZZ | Deutsche Bank | -- | Buy | -- | $152 | July 15, 2025 |
| Upgrade | JAZZ | UBS | Neutral | Buy | $145 | $179 | March 7, 2025 |
| Downgrade | JAZZ | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Feb. 26, 2025 |
| Upgrade | JAZZ | Wells Fargo | Equal Weight | Overweight | $130 | $170 | Feb. 13, 2025 |
| Upgrade | JAZZ | Morgan Stanley | Equal Weight | Overweight | $140 | $175 | Dec. 12, 2024 |
News
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.
Read More
Wall Street Analysts See a 29.63% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Best Momentum Stocks to Buy for March 3rd
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STRL. BATRA and JAZZ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 3, 2025.
Read More
4 Stocks Trading Near 52-Week High With More Upside Potential
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Stocks like NFG, ENS, TAP and JAZZ are seeing price strength and have a high chance of carrying the momentum forward.
Read More
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.
Read More
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Read More
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.
Read More
About Jazz Pharmaceuticals plc (JAZZ)
- IPO Date 2007-06-01
- Website https://www.jazzpharma.com
- Industry Biotechnology
- CEO Bruce C. Cozadd
- Employees 2800